Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Shield Bio

Shield Bio

A biotechnology company offering a DNA sequencing platform for helping to prevent antibiotic resistance.

Shield Bio, formerly known as TL Biolabs, was a biotechnology company offering a DNA sequencing platform for helping to prevent antibiotic resistance headquartered in San Jose, California. It was founded in 2016 by Fred Turner and Sam Parlett.

The company's platform allowed for the genomic testing and identification of antibiotic strains of gonorrhea, and other pathogens exhibiting antibiotic resistance.

Funding
Seed

On February 23, 2017 Shield Bio announced raising $4.1 million in seed funding from Andreessen Horowitz (lead investor), Soma Capital, SGH Capital, Refactor Capital, Friale, and Josh Buckley.

Series A

On May 23, 2018 Shield Bio announced raising $8 million in series A funding from Refactor Capital (lead investor), Andreessen Horowitz (lead investor), iSELECT FUND, Zeno Ventures, Y Combinator, Valia Ventures, Tectonic Capital, Summit Action, Sinai Ventures, Soma Capital, and Sean Rad.

Timeline

May 23, 2018
Shield Bio raises a $8,000,000 seed round from Andreessen Horowitz, Refactor Capital, Sean Rad, Sinai Ventures, Soma Capital, Summit Action, Tectonic Capital, Y Combinator, Zeno Ventures and iSelect Fund.
February 23, 2017
Shield Bio raises a $4,100,000 seed round from Andreessen Horowitz, Refactor Capital, SGH Capital and Soma Capital.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.